Mark is a cardiologist with a focus on building innovative systems of care for heart failure patients. He is an active contributor to generative artificial intelligence development on assignment at Meta Platforms and collaborated with Anumana (a Mayo Clinic incubator company) on the development of artificial intelligence software to predict low left ventricular ejection fraction via 12-lead ECG. Mark served as executive medical director of heart failure and cardiovascular medical affairs at Novartis, as well as on the steering committees of American Heart Association’s IMPLEMENT-HF implementation science program.

Having extensive experience with invasive pulmonary artery pressure and non-invasive transthoracic lung fluid monitoring in clinical practice, he continues to innovate on proactive and preventative detection tools to maximize patient healthspan, reduce the cost of care delivery, and to promote care access and equity.

He earned his medical degree at Saint Louis University School of Medicine. Internal medicine residency, cardiovascular diseases fellowship, and Bugher molecular cardiology post-doctoral fellowship training were all accomplished at Baylor College of Medicine. He also served 14 years in the U.S. Army and Army National Guard as a field surgeon and brigade surgeon. He is a Fellow of the Heart Failure Society of America.